Scott Brunner

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, dives deep into the world of compounding pharmacies. He discusses the struggle between compounding and big pharmaceutical companies, particularly against giants like Eli Lilly and Novo Nordisk. The conversation touches on regulatory challenges, including the 5% rule and a contentious list of hard-to-compound medications. Brunner also highlights the increasing demand for GLP-1 drugs and the implications for patient access, advocating passionately for the future of compounded medications.